Skip to content

An evaluation on the efficacy and safety of intralesional injectable platelet-rich fibrin (i-PRF) versus Triamcinolone Acetonide injection in the treatment of erosive oral lichen planus: a randomized controlled trial

An evaluation on the efficacy and safety of intralesional injectable platelet-rich fibrin (i-PRF) versus Triamcinolone Acetonide injection in the treatment of erosive oral lichen planus: a randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034747
Enrollment
Unknown
Registered
2020-07-17
Start date
2020-08-03
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

erosive oral lichen planus

Interventions

experimental group:intralesional i-PRF injection, another intralesional injectiom a week later if the lesion not healed
controlled group:intralesional triamcinolone acetonide injection, another intralesional injectiom a week later if the lesion not healed

Sponsors

Hospital of Stomatology Affiliated to Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. A subject diagnosed as an erosive oral lichen planus based on medical history, clinical manifestations, and/or pathological findings; Who aged >=18 years old, and the relevant treatment is not taken for this disease; 2. The age of onset is 18 to 60 years old, and the relevant treatment is not taken for this disease; 3. Lesion area<=3cm2; 4. No blood system disease; 5. Patients who agree and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Conmbined with other identified oral mucosal diseases; 2. The location of erosion is not conducive to observation and measurement; 3. Histological signs of dysplasia; 4. Certain drugs or amalgam fillings may cause mossy-like reactions; 5. Those who have used antibiotics within 3.1 months and have used immunologic preparations within 3 months; 6. Pregnant women, lactating women; 7. Allergies and a history of allergies to drugs and food; 8. Patients with systemic diseases such as autoimmune related diseases, diabetes, hepatitis C and tumor that seriously affect lichen planus; 9. Those who do not follow medical advice or are unable to return on time.

Design outcomes

Primary

MeasureTime frame
The degree of pain (Visual Analogue Scale, VAS);

Secondary

MeasureTime frame
erosive lesion area;

Countries

China

Contacts

Public ContactJuanjuan Zong

Hospital of Stomatology Affiliated to Nanchang University

jj-671109@163.com+86 13970065267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026